| [1] |
Braun M, Frieden IJ, Siegel DH, et al. Multicenter study of long⁃term outcomes and quality of life in PHACE syndrome after age 10[J]. J Pediatr, 2024,267:113907. DOI: 10.1016/j.jpeds.2024. 113907.
|
| [2] |
Cotton CH, Ahluwalia J, Balkin DM, et al. Association of demographic factors and infantile hemangioma characteristics with risk of PHACE syndrome[J]. JAMA Dermatol, 2021,157(8):1⁃8. DOI: 10.1001/jamadermatol.2021.1901.
|
| [3] |
Garzon MC, Epstein LG, Heyer GL, et al. PHACE syndrome: consensus⁃derived diagnosis and care recommendations[J]. J Pediatr, 2016,178:24⁃33. DOI: 10.1016/j.jpeds.2016.07.054.
|
| [4] |
Braun MT, Mathes EF, Siegel DH, et al. Facing PHACE twenty⁃five years later: review and perspectives on management[J]. J Vasc Anom, 2021,2(4):e027. DOI: 10.1097/JOVA.000000000 0000027.
|
| [5] |
Kalambe AS, Sugihara K, Yamamoto K, et al. PHACE(S) syndrome with ocular involvements and no periocular hemangioma[J]. Case Rep Ophthalmol, 2023,14(1):477⁃483. DOI: 10.1159/000533887.
|
| [6] |
Sepulveda W, Sepulveda F. Fetal neuroimaging findings in PHACE syndrome: case report and review of the literature[J]. J Matern Fetal Neonatal Med, 2022,35(14):2751⁃2758. DOI: 10. 1080/14767058.2020.1799349.
|
| [7] |
章开智, 邱桐, 周江元, 等. 口服普萘洛尔治疗增殖期婴儿血管瘤的时机选择[J]. 中华皮肤科杂志, 2025,58(10):952⁃956. DOI: 10.35541/cjd.20250003.
|
| [8] |
Schmid F, Hoeger PH. Propranolol response in patients with segmental versus focal facial hemangiomas: a retrospective case⁃control study[J]. J Am Acad Dermatol, 2022,87(2):490⁃491. DOI: 10.1016/j.jaad.2021.10.054.
|
| [9] |
Hermans MM, Pasmans S, de Laat P, et al. Propranolol or atenolol for the management of infantile hemangioma: Implications for long⁃term health[J]. JAAD Int, 2023,11:137⁃139. DOI: 10.1016/j.jdin.2023.02.001.
|
| [10] |
Ahuja R, Tyagi M, Kumar A, et al. PHACES syndrome⁃associated large segmental facial hemangioma successfully treated with oral itraconazole[J]. Int J Dermatol, 2025,64(4):731⁃732. DOI: 10.1111/ijd.17442.
|
| [11] |
Negosanti F, Silvestri M, Bennardo L, et al. Nd:YAG laser in association with pulsed dye laser for the treatment of PHACES syndrome[J]. Dermatol Reports, 2021,13(1):8751. DOI: 10. 4081/dr.2021.8751.
|
| [12] |
Iacobas I, Burrows PE, Frieden IJ, et al. LUMBAR: association between cutaneous infantile hemangiomas of the lower body and regional congenital anomalies[J]. J Pediatr, 2010,157(5):795⁃801.e1⁃e7. DOI: 10.1016/j.jpeds.2010.05.027.
|
| [13] |
Barrios L, Chamlin S, Keppler⁃Noreuil KM, et al. LUMBAR syndrome⁃OEIS complex overlap: a case series and review[J]. Am J Med Genet A, 2024,194(7):e63582. DOI: 10.1002/ajmg.a.63582.
|
| [14] |
Metry D, Copp HL, Rialon KL, et al. Delphi consensus on diagnostic criteria for LUMBAR syndrome[J]. J Pediatr, 2024,272:114101. DOI: 10.1016/j.jpeds.2024.114101.
|
| [15] |
Arnold JD, Yoon S, Shah N, et al. Characteristics and complications of anogenital infantile hemangiomas: a multicenter retrospective analysis[J]. J Am Acad Dermatol, 2023,89(5):1015⁃1021. DOI: 10.1016/j.jaad.2023.06.049.
|
| [16] |
Drolet BA, Chamlin SL, Garzon MC, et al. Prospective study of spinal anomalies in children with infantile hemangiomas of the lumbosacral skin[J]. J Pediatr, 2010,157(5):789⁃794. DOI: 10. 1016/j.jpeds.2010.07.054.
|
| [17] |
Shah A, Tollefson M, Ahn ES, et al. Successful treatment of ulcerated hemangioma with diversion colostomy in a neonate with LUMBAR syndrome[J]. J Surg Case Rep, 2024,2024(3):rjae114. DOI: 10.1093/jscr/rjae114.
|
| [18] |
Ji Y, Chen S, Yang K, et al. Screening for infantile hepatic hemangioma in patients with cutaneous infantile hemangioma: a multicenter prospective study[J]. J Am Acad Dermatol, 2021,84(5):1378⁃1384. DOI: 10.1016/j.jaad.2020.11.062.
|
| [19] |
Li L, Yu L, Xu Z, et al. Clinical features of cutaneous infantile hemangioma combined with asymptomatic infantile hepatic hemangioma and efficacy of propranolol treatment[J]. J Cosmet Dermatol, 2023,22(12):3369⁃3374. DOI: 10.1111/jocd.15823.
|
| [20] |
中华医学会整形外科分会血管瘤脉管畸形学组.血管瘤与脉管畸形诊疗指南(2024版)[J].组织工程与重建外科杂志,2024,20(1):1⁃50. DOI: 10.3969/j.issn.1673⁃0364.2024.01.001.
|
| [21] |
Gong X, Li Y, Yang K, et al. Infantile hepatic hemangiomas: looking backwards and forwards[J]. Precis Clin Med, 2022,5(1):pbac006. DOI: 10.1093/pcmedi/pbac006.
|
| [22] |
Siano MA, Ametrano O, Barbato F, et al. Consumptive hypothyroidism due to hepatic hemangiomas: a case series and review of the literature[J]. JPGN Rep, 2022,3(4):e270. DOI: 10.1097/PG9.0000000000000270.
|
| [23] |
Horii KA, Drolet BA, Frieden IJ, et al. Prospective study of the frequency of hepatic hemangiomas in infants with multiple cutaneous infantile hemangiomas[J]. Pediatr Dermatol, 2011,28(3):245⁃253. DOI: 10.1111/j.1525⁃1470.2011.01420.x.
|
| [24] |
Esposito F, D'Auria D, Ferrara D, et al. Hepatic hemangiomas in childhood: the spectrum of radiologic findings. A pictorial essay[J]. J Ultrasound, 2023,26(1):261⁃276. DOI: 10.1007/s40477⁃022⁃00714⁃y.
|
| [25] |
Ray G, Das K, Sarkar A, et al. Propranolol monotherapy in multifocal/diffuse infantile hepatic hemangiomas in Indian children: a case series[J]. J Clin Exp Hepatol, 2023,13(4):707⁃712. DOI: 10.1016/j.jceh.2023.02.005.
|
| [26] |
Yang K, Peng S, Chen L, et al. Efficacy of propranolol treatment in infantile hepatic haemangioma[J]. J Paediatr Child Health, 2019,55(10):1194⁃1200. DOI: 10.1111/jpc.14375.
|
| [27] |
Moon SJ, Baek HJ, Kim BR, et al. Successful management of massive congenital hepatic hemangioma and systemic hypertension with sirolimus[J]. J Pediatr Hematol Oncol, 2022,44(2):e424⁃e427. DOI: 10.1097/MPH.0000000000002146.
|
| [28] |
Tang T, Wang X, Mao Y, et al. Real⁃world data on the clinicopathological traits and outcomes of hospitalized liver hemangioma patients: a multicenter study[J]. Ann Transl Med, 2021,9(13):1067. DOI: 10.21037/atm⁃20⁃4684.
|
| [29] |
Mack JM, Crary SE. How we approach coagulopathy with vascular anomalies[J]. Pediatr Blood Cancer, 2022,69 Suppl 3:e29353. DOI: 10.1002/pbc.29353.
|
| [30] |
Yao W, Li KL, Qin ZP, et al. Standards of care for Kasabach⁃Merritt phenomenon in China[J]. World J Pediatr, 2021,17(2):123⁃130. DOI: 10.1007/s12519⁃020⁃00379⁃9.
|
| [31] |
Zhou J, Lan Y, Qiu T, et al. Impact of age and tumor size on the development of the Kasabach⁃Merritt phenomenon in patients with kaposiform hemangioendothelioma: a retrospective cohort study[J]. Precis Clin Med, 2023,6(2):pbad008. DOI: 10.1093/pcmedi/pbad008.
|
| [32] |
Ji Y, Chen S, Yang K, et al. Kaposiform hemangioendothelioma: current knowledge and future perspectives[J]. Orphanet J Rare Dis, 2020,15(1):39. DOI: 10.1186/s13023⁃020⁃1320⁃1.
|
| [33] |
Peng S, Xia C, Yang K, et al. Kaposiform haemangioendothelioma: magnetic resonance imaging features in 64 cases[J]. BMC Pediatr, 2021,21(1):107. DOI: 10.1186/s12887⁃021⁃02573⁃8.
|
| [34] |
Huo J, Chen S, Li J, et al. Retroperitoneal kaposiform hemangioendothelioma with kasabach⁃merritt phenomenon in children: a case report and review of the literature[J]. Front Pediatr, 2023,11:1138689. DOI: 10.3389/fped.2023.1138689.
|
| [35] |
卡波西样血管内皮瘤诊疗专家共识小组. 卡波西样血管内皮瘤诊疗中国专家共识(2023)[J]. 中华小儿外科杂志, 2024,45(1):1⁃9. DOI: 10.3760/cma.j.cn421158⁃20231019⁃00419.
|
| [36] |
Ji Y, Chen S, Zhou J, et al. Sirolimus plus prednisolone vs sirolimus monotherapy for kaposiform hemangioendothelioma: a randomized clinical trial[J]. Blood, 2022,139(11):1619⁃1630. DOI: 10.1182/blood.2021014027.
|
| [37] |
Sun X, Xu M, Lv K, et al. Comprehensive therapy for infant vascular tumor associated with Kasabach⁃Merritt phenomenon⁃single⁃center primary experience[J]. Front Pediatr, 2022,10:924422. DOI: 10.3389/fped.2022.924422.
|
| [38] |
Lissa FC, Argente JS, Antunes GN, et al. Maffucci syndrome and soft tissue sarcoma: a case report[J]. Int Semin Surg Oncol, 2009,6:2. DOI: 10.1186/1477⁃7800⁃6⁃2.
|
| [39] |
Chen C, Li J, Jiang T, et al. IDH mutations are potentially the intrinsic genetic link among the multiple neoplastic lesions in Ollier disease and Maffucci syndrome: a clinicopathologic analysis from a single institute in Shanghai, China[J]. Diagnostics (Basel), 2022,12(11):2764. DOI: 10.3390/diagnostics 12112764.
|
| [40] |
Khan MT, Arooj S, Mukhtar MU, et al. Maffucci syndrome: case report and review of diagnostic signs of the rare disease[J]. Radiol Case Rep, 2022,17(10):3674⁃3677. DOI: 10.1016/j.radcr.2022.07.008.
|
| [41] |
El Abiad JM, Robbins SM, Cohen B, et al. Natural history of Ollier disease and Maffucci syndrome: patient survey and review of clinical literature[J]. Am J Med Genet A, 2020,182(5):1093⁃1103. DOI: 10.1002/ajmg.a.61530.
|
| [42] |
Verdegaal SH, Bovée JV, Pansuriya TC, et al. Incidence, predictive factors, and prognosis of chondrosarcoma in patients with Ollier disease and Maffucci syndrome: an international multicenter study of 161 patients[J]. Oncologist, 2011,16(12):1771⁃1779. DOI: 10.1634/theoncologist.2011⁃0200.
|
| [43] |
Triki W, Belem A, Labbene E, et al. Malignant transformation of Maffucci syndrome[J]. J Clin Rheumatol, 2021,27(7):e266⁃e268. DOI: 10.1097/RHU.0000000000001424.
|
| [44] |
Verma GG, Jain VK, Iyengar KP. Monomelic Maffucci syndrome[J]. BMJ Case Rep, 2021,14(3):e239619. DOI: 10.1136/bcr⁃2020⁃239619.
|
| [45] |
Lv H, Jiang H, Zhang M, et al. Maffucci syndrome complicated by giant chondrosarcoma in the left ankle with an IDH1 R132C mutation: a case report[J]. World J Surg Oncol, 2022,20(1):218. DOI: 10.1186/s12957⁃022⁃02686⁃z.
|
| [46] |
He R, Wang Y, Ma L, et al. Successful sirolimus treatment of spindle cell haemangiomas in a paediatric patient with Maffucci syndrome[J]. Clin Exp Dermatol, 2024,49(5):540⁃542. DOI: 10.1093/ced/llae018.
|
| [47] |
Lekwuttikarn R, Chang J, Teng J. Successful treatment of spindle cell hemangiomas in a patient with Maffucci syndrome and review of literatures[J]. Dermatol Ther, 2019,32(3):e12919. DOI: 10.1111/dth.12919.
|